Overview

Aumolertinib in Treatment of Resectable Stage IA EGFRm+ NSCLC: a Multi-center, Single-arm Clinical Trial

Status:
Not yet recruiting
Trial end date:
2025-10-15
Target enrollment:
Participant gender:
Summary
Efficacy and safety of postoperative adjuvant treatment of NSCLC patients with Aumolertinib.
Phase:
Phase 2
Details
Lead Sponsor:
Baohui Han
Collaborator:
Jiangsu Hansoh Pharmaceutical Co., Ltd.